Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
7,807 total articles
ASML Holding NV reported Q1 2026 total net sales of €8.8 billion and net income of €2.8 billion, with a gross margin of 53%. The company raised its 2026 total net sales guidance to between €36 billion and €40 billion and expects full-year gross margins of 51%-53%, supported by strong demand driven by AI-related semiconductor investments. ASML also …
KANZHUN LIMITED, operating under the brand BOSS Zhipin, announced that it has exceeded RMB862 million in share repurchases in 2026, including a recent buyback of 587,254 shares worth RMB27.2 million as part of its ongoing program aimed at returning value to shareholders.
Five Star Bancorp (Nasdaq: FSBC) announced the expansion of its operations in Southern California by adding five experienced banking professionals to support growth initiatives in the Greater Los Angeles Area. The move includes plans to open a new office and aims to enhance service to middle-market businesses leveraging the bank's concierge style a…
AMC Robotics Corporation announced a delay in filing its Annual Report on Form 10-K for the fiscal year ending December 31, 2025, beyond the SEC deadline of April 15, 2026. The delay is due to additional time needed to finalize accounting treatment for warrants issued in a prior private financing tied to its business combination with AlphaVest Acqu…
Terra Innovatum Global N.V. announced it will host a business update call to inform investors of its progress as it advances into the manufacturing execution phase of its SOLO™ Micro-Modular Reactor. The company is finalizing its 2025 Form 10-K filing, ensuring compliance with post-combination reporting requirements with Nasdaq, and will discuss re…
Great Southern Bancorp, Inc. announced preliminary earnings for Q1 2026 of $1.58 per diluted common share, up from $1.47 in Q1 2025. Net income was $17.5 million, supported by loan growth in construction and commercial real estate, stable deposits, strong capital ratios, and disciplined expense management. Asset quality remained solid with low non-…
Woodward, Inc. has agreed to sell its pilot controls product line and related services to Ontic Engineering and Manufacturing, aiming to optimize its portfolio and concentrate on core aerospace growth areas. A long-term supply and transition service agreement will ensure continuity. The move complements Woodward's recent strategic initiatives in ae…
Lightbridge Corporation has received a Notice of Allowance from the European Patent Office for its advanced multi-zone nuclear fuel element and additive manufacturing process, extending patent protection across key European nuclear markets. This development validates Lightbridge's proprietary fuel technology innovation and supports the company's co…
NRx Pharmaceuticals has established NRx Defense Systems, a new R&D subsidiary focused on developing combined neuroplastic therapies that integrate D-cycloserine with robotic-enabled transcranial magnetic stimulation (TMS) for the treatment of depression and PTSD in military and first responder populations. Led by Dr. Dennis K. McBride and partnerin…
USA Rare Earth, Inc., through its subsidiary Less Common Metals Ltd., has successfully completed the first commercial production of high-purity yttrium metal. This achievement establishes the company as one of the few non-Chinese producers of commercial-grade yttrium metal, critical for aerospace, defense, and advanced manufacturing sectors. The co…
CECO Environmental Corp., a Nasdaq-listed industrial environmental solutions company, will release its Q1 2026 financial results premarket on April 28, followed by a live webcast earnings call. The company serves diverse industrial sectors with air and water quality solutions, including energy transition markets and manufacturing sectors.
Cibus, Inc., an agricultural technology company specializing in gene editing for crop traits, announced the election of Thomas Urban to its Board of Directors. Urban brings extensive agribusiness experience and is expected to support Cibus's commercialization initiatives and strategic growth plans. The company focuses on licensing its proprietary p…
Tonix Pharmaceuticals announced the publication of pharmacokinetic data for TONMYA® (cyclobenzaprine HCl sublingual tablets) after 20 days of dosing, supporting its FDA-approved regimen for fibromyalgia treatment. The study highlights TONMYA’s rapid absorption, improved bioavailability, and favorable safety profile, reinforcing the drug's potential…
Energous Corporation reported sustained commercial momentum entering 2026, highlighting expanding deployments with two Fortune 10 customers including international expansion, and a growing pipeline of proof-of-concept initiatives across retail, manufacturing, foodservice, and government sectors. The company also announced increased domestic manufac…
BioCryst Pharmaceuticals announced that it will report its Q1 2026 financial results on May 6, 2026, followed by a conference call and webcast to discuss the results and provide a corporate update. The company focuses on developing and commercializing therapies for hereditary angioedema and other rare diseases.
Stereotaxis, a NYSE-listed leader in surgical robotics, entered into a definitive agreement to acquire Robocath, a French innovator in robotic technologies for interventional cardiology and neurointerventions. The acquisition aims to combine complementary robotic technologies to provide an integrated platform for a broad range of endovascular proce…
Dime Community Bancshares, a New York-based bank holding company, announced the appointment of Meyer Eichler as Executive Vice President and Managing Executive Director. Eichler will focus on expanding Dime's presence within the Orthodox Jewish community in New York and New Jersey, targeting key sectors such as healthcare, real estate, retail, whol…
Medicus Pharma announced new Phase 1 clinical data for Teverelix, its investigational long-acting GnRH antagonist, demonstrating predictable estradiol suppression, favorable pharmacokinetics for infrequent dosing, and good safety profile. The findings support advancing Teverelix development for hormone-driven conditions including endometriosis and …
Bitdeer Technologies Group announced significant operational growth in March 2026, including a 480% year-over-year increase in Bitcoin production to 661 BTC and a 105% month-over-month rise in AI cloud annual recurring revenue to approximately $43 million. The company is expanding its AI and Bitcoin mining infrastructure, advancing new colocation d…
TG Therapeutics announced the completion of enrollment for its Phase 3 trial testing subcutaneous delivery of BRIUMVI, an anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS). The study compares two dosing regimens administered subcutaneously to the existing intravenous formulation, aiming to demonstrate non-inferiority in drug expo…
Prelude Therapeutics announced the appointment of Dr. Charles Morris as Chief Medical Officer effective April 20, 2026. Dr. Morris brings over 30 years of oncology drug development experience and will support Prelude's advancing clinical programs targeting myeloproliferative neoplasms and ER+ breast cancer, with clinical development expected to beg…
Ridgepost Capital, a leading provider in private markets solutions, announced it will release its Q1 2026 financial results on May 7, 2026, prior to the U.S. market open. The company will also host an earnings conference call the same day to discuss results and outlook. Ridgepost Capital manages over $43 billion in assets, focusing on Private Equit…
Arbutus Biopharma announced that the U.S. FDA has granted Fast Track designation for their RNAi therapeutic imdusiran targeting chronic hepatitis B. This designation may accelerate the drug’s review and development, offering potential benefits such as earlier FDA interactions and expedited approval pathways. Clinical trials showed promising results…
Plus Therapeutics, a clinical-stage healthcare company specializing in precision diagnostics and radiopharmaceuticals for CNS cancers, has appointed Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR. Goodman brings over 20 years of experience in health economics, market access, and payer engagement, expected to fortify Plus The…
Alterity Therapeutics announced a virtual event featuring key opinion leaders to discuss insights on their lead drug candidate ATH434 for Multiple System Atrophy (MSA). The company will review Phase 2 clinical trial results demonstrating clinical efficacy and provide a high-level overview of the planned Phase 3 pivotal trial. The event aims to info…
